 |
|
|
| |
RANDOMIZED, OPEN-LABEL, 12-WEEK COMPARISON OF CONTROLLED-RELEASE INTERFERON ALPHA2B + RIBAVRIN VS. PEGYLATED-INTERFERON ALPHA2B + RIBAVRIN IN TREATMENT-NA&x#207;VE GENOTYPE1 HEPATITIS C: 4 WEEK RESULTS FROM 480STUDY (PANEL A)
|
| |
| |
Reported by Jules Levin
EASL Apr 14-18 2010 Vienna Austria
Inclusion/Exclusion Criteria
480 STUDY Panel A: Injection Site Reaction Signs As Recorded By Investigators
|
| |
|
|
|
|
|
